https://www.selleckchem.com/products/skf96365.html
BACKGROUND Oncology guidelines suggest using the Khorana score to select ambulatory cancer patients receiving chemotherapy for primary venous thromboembolism (VTE) prevention, but its performance in different cancers remains uncertain. OBJECTIVE To examine the performance of the Khorana score in assessing 6-month VTE risk, and the efficacy and safety of LMWH among high-risk Khorana score patients. METHODS This individual patient data meta-analysis evaluated (ultra)-low-molecular-weight heparin (LMWH) in patients with solid cancer using
Like
Comment
Share
